


Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 089048-0299		SERIAL NO. 10/645,557	
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)				APPLICANT Jhi-Joung WANG			
				FILING DATE 01/22/03		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
RD		3,433,791	03/18/1969	Bentley et al.			
RD		6,004,969	12/21/1999	Hu			
RD		5,750,534	05/12/1998	Yoa-Pu et al.			
RD		6,225,321 B1	05/01/2001	Hu et al.			
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
RD		WO 96/28451	9/19/96	PCT	C07D	489/02	
RD		WO 96/16063	5/30/96	PCT	C07D	489/02	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
RD		Hayes et al., "Determination of Receptors that Mediate Opiate Side Effects in the Mouse", Br. J. Pharmac. (1983), 79, 731-736.					
RD		Baxter et al., "Prevention of Epidural Morphine-induced Respiratory Depression with Intravenous Nalbuphine Infusion in Post-Thoracotomy Patients", Canadian Journal of Anaesthesia (1989) 36:5, pp. 503-509.					
RD		Bickel et al., "A Clinical Trial of Buprenorphine: Comparison with Methadone in the Detoxification of Heroin Addicts", Clinical Pharmacology Therapeutics, January, 1988, Vol. 43, No. 1, pp. 72-78.					
RD		Fudala et al., "Use of Buprenorphine in the Treatment of Opioid Addiction. II. Physiologic and Behavioral Effects of Daily and Alternate-day Administration and Abrupt Withdrawal", Clinical Pharmacology Therapeutics, April 1990, Vol 47, No. 4, pp. 525-534.					
RD		Imoto et al., "Transdermal Prodrug Concepts: Permeation of Buprenorphine and Its Alkyl Esters through Hairless Mouse Skin and Influence of Vehicles", Biological Pharmaceutical Bulletin, February 1996, Vol. 19, No. 2 pp. 263-267.					
RD		Stinchcomb et al., "Permeation of Buprenorphine and its 3-Alkyl-Ester Prodrugs Through Human Skin", Pharmaceutical Research, Vol. 13, No. 10., pp. 1519-1523.					
RD		Kuhlman et al., "Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine", Journal of Analytical Toxicology, October, 1996, Vol. 20, No. 6, pp. 337-516.					
RD		Stinchcomb et al., "A Solubility and Related Physicochemical Property Comparison of Buprenorphine and Its 3-Alkyl Esters", Pharmaceutical Research,					





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Date Submitted: August 25, 2006

(use as many sheets as necessary)

## Complete if Known

Application Number	10/645,557
Filing Date	08/22/2003
First Named Inventor	Jhi-Joung WANG
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	089048-0299

Sheet

1

of

1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RD	B1	JP	07-196510		NIPPON SEIYAKU KK	8/1/1995		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RD	B2	Audra L. STINCHCOMB et al., "Permeation of Buprenorphine and Its 3-Alkyl-Ester Prodrugs Through Human Skin", Pharmaceutical Research, 13(10), 1519-1523, 1996.	

Examiner  
Signature

/Rita Desai/

Date  
Considered

09/15/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.